Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: A pilot study

Supportive Care in Cancer

Volumn 20, Issue 2, 2012, Pages 375-384

  Amodeo, Laura ^a   Castelli, Lorys ^a   Leombruni, Paolo ^a   Cipriani, Daniela ^a   Biancofiore, Alessia ^a   Torta, Riccardo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer; Mood disorder; Paroxetine; Slow titration

Indexed keywords

PAROXETINE;

ADULT; AGED; ANXIETY; ANXIETY DISORDER; ARTICLE; ASTHENIA; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; NAUSEA; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS;

ADJUSTMENT DISORDERS; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG ADMINISTRATION SCHEDULE; DYSTHYMIC DISORDER; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; PAROXETINE; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 84855198107     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1118-8     Document Type: Article

References (44)

1. D Spiegel J Giese-Davis 2003 Depression and cancer: mechanisms and disease progression Biol Psychiatry 54 3 269 282 12893103 10.1016/S0006-3223(03) 00566-3 (Pubitemid 37267857)
2. M Hamer Y Chida GJ Molloy 2009 Psychological distress and cancer mortality J Psychosom Res 66 3 255 258 19232239 10.1016/j.jpsychores.2008.11.002 Epub 2009 Jan 16
3. E Smith S Gomm C Dickens 2003 Assessing the independent contribution to quality of life from anxiety and depression in patients with advanced cancer Palliat Med 17 6 509 513 14526884 10.1191/0269216303pm781oa 1:STN:280: DC%2BD3svmsVOnuw%3D%3D (Pubitemid 37160890)
4. MJ Massie 2004 Prevalence of depression in patients with cancer J Natl Cancer Inst Monogr 2004 32 57 71 10.1093/jncimonographs/lgh014
5. Pirl WF (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr (32):32-39
6. AF Angelino GJ Treisman 2001 Major depression and demoralization in cancer patients: diagnostic and treatment considerations Support Care Cancer 9 5 344 349 11497387 10.1007/s005200000195 1:STN:280:DC%2BD3MvltFCqtg%3D%3D (Pubitemid 32666884)
7. G Rodin N Lloyd M Katz E Green JA Mackay RK Wong 2007 The treatment of depression in cancer patients: a systematic review Support Care Cancer 15 2 123 136 17058100 10.1007/s00520-006-0145-3 Epub 2006 Oct 21 (Pubitemid 46332931)
8. V Strong R Waters C Hibberd G Murray L Wall J Walker G McHugh A Walker M Sharpe 2008 Management of depression for people with cancer (SMaRT oncology 1): a randomised trial Lancet 372 9632 40 48 18603157 10.1016/S0140-6736(08)60991-5 (Pubitemid 351899234)
9. R Torta I Siri P Caldera 2008 Sertraline effectiveness and safety in depressed oncological patients Support Care Cancer 16 1 83 91 17874143 10.1007/s00520-007-0269-0 Epub 2007 Sep 14 (Pubitemid 350243754)
10. G Rodin 2008 Treatment of depression in patients with cancer Lancet 372 9632 8 10 18603142 10.1016/S0140-6736(08)60968-X (Pubitemid 351899219)
11. SA Bull XH Hu EM Hunkeler, et al. 2002 Discontinuation of use and switching of antidepressants: influence of patient-physician communication JAMA 288 1403 1409 12234237 10.1001/jama.288.11.1403 (Pubitemid 35025915)
12. CM Beasley Jr SC Koke ME Nilsson JS Gonzales 2000 Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis Clin Ther 22 1319 1330 11117656 10.1016/S0149-2918(00)83028-3 1:CAS:528:DC%2BD3cXptVagtbk%3D
13. KA Kobak L Taylor DJ Katzelnick, et al. 2002 Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence J Clin Psychiatry 63 727 732 12197454 10.4088/JCP.v63n0811
14. PS Masand 2003 Tolerability and adherence issues in antidepressant therapy Clin Ther 25 8 2289 2304 14512135 10.1016/S0149-2918(03)80220-5 1:CAS:528:DC%2BD3sXnvVWhtLY%3D (Pubitemid 37076320)
15. AS Young R Klap CD Sherbourne KB Wells 2001 The quality of care for depressive and anxiety disorders in the United States Arch Gen Psychiatry 58 55 61 11146758 10.1001/archpsyc.58.1.55 1:STN:280:DC%2BD3M7jvFKitg%3D%3D (Pubitemid 32057765)
16. JU Rosholm M Andersen LF Gram 2001 Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study Eur J Clin Pharmacol 56 923 929 11317482 10.1007/s002280000234 1:CAS:528:DC%2BD3MXitFehsrc%3D (Pubitemid 33788571)
17. H Onishi W Yamamoto M Wada T Nishida, et al. 2007 Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: case reports and review of the literature Palliat Support Care 5 4 411 414 18044419 10.1017/S1478951507000612
18. LI Sinclair DM Christmas SD Hood JP Potokar, et al. 2009 Antidepressant-induced jitteriness/anxiety syndrome: systematic review Br J Psychiatry 194 6 483 490 19478285 10.1192/bjp.bp.107.048371
19. C Barbui M Hotopf N Freemantle J Boynton, et al. 2007 WITHDRAWN: treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs) Cochrane Database Syst Rev 18 3 CD002791
20. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, fourth edition, text revision. American Psychiatric Association, Washington
21. SA Montgomery M Asberg 1979 A new depression scale designed to be sensitive to change Br J Psychiatry 134 382 389 444788 10.1192/bjp.134.4.382 1:STN:280:DyaE1M7ovVCksg%3D%3D (Pubitemid 9136500)
22. Guy W. (1976) DOTES: dosage record and treatment emergent symptom scale. In: Rockville GW (ed) ECDEU assessment manual for psychopharmacology, rev. ed. National Institute of Mental Health Rockville, MD, USA.
23. Conti L. Gli effetti indesiderati dei trattamenti psicofarmacologici. (2000) In Conti L. "Repertorio delle scale di valutazione in psichiatria". S.E.E. (ed) Firenze, Italy. p. 1533-1544
24. DL Musselman DH Lawson JF Gumnick AK Manatunga, et al. 2001 Paroxetine for the prevention of depression induced by high-dose interferon alfa N Engl J Med 344 961 966 11274622 10.1056/NEJM200103293441303 1:CAS:528: DC%2BD3MXislyktrc%3D (Pubitemid 32240314)
25. AS Zigmond RP Snaith 1983 The hospital anxiety and depression scale Acta Psychiatr Scand 67 361 370 6880820 10.1111/j.1600-0447.1983.tb09716.x 1:STN:280:DyaL3s3nvFWjug%3D%3D (Pubitemid 13098606)
26. NP Kearns CA Cruickshank KJ McGuigan SA Riley SP Shaw RP Snaith 1982 A comparison of depression rating scales Br J Psychiatry 141 45 49 7116071 10.1192/bjp.141.1.45 1:STN:280:DyaL3s%2FgtFSmsw%3D%3D (Pubitemid 12074468)
27. M Zimmerman MA Posternak I Chelminski 2004 Implications of using different cut-offs on symptom severity scales to define remission from depression Int Clin Psychopharmacol 19 4 215 220 15201568 10.1097/01.yic. 0000130232.57629.46 (Pubitemid 38901649)
28. M Costantini M Musso P Viterbori F Bonci L Del Mastro O Garrone M Venturini G Morasso 1999 Detecting psychological distress in cancer patients: validity of the Italian version of the hospital anxiety and depression scale Support Care Cancer 7 3 121 127 10335929 10.1007/s005200050241 1:STN:280:DyaK1M3ms12lsg%3D%3D (Pubitemid 29187558)
29. M Zimmerman MA Posternak I Chelminski 2004 Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression J Psychiatr Res 38 6 577 582 15458853 10.1016/j.jpsychires.2004.03.007 (Pubitemid 39348889)
30. M Hamilton 1959 The assessment of anxiety states by rating Br J Med Psychol 32 50 55 13638508 10.1111/j.2044-8341.1959.tb00467.x 1:STN:280:DyaG1M%2FmvVWisQ%3D%3D
31. Rayner L, Price A, Evans A, Valsraj K, Higginson IJ, Hotopf M (2010) Antidepressants for depression in physically ill people. Cochrane Database Syst Rev (3):CD007503. doi: 10.1002/14651858.CD007503.pub2
32. S Williams J Dale 2006 The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review Br J Cancer 94 372 390 16465173 10.1038/sj.bjc.6602949 1:STN:280: DC%2BD28%2FnvVehtg%3D%3D (Pubitemid 43237562)
33. MJ Fisch PJ Loehrer J Kristeller S Passik, et al. 2003 Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier oncology group J Clin Oncol 21 1937 1943 12743146 10.1200/JCO.2003.08.025 1:CAS:528:DC%2BD2cXptlCksbw%3D (Pubitemid 46606381)
34. GR Morrow JT Hickok JA Roscoe RF Raubertas, et al. 2003 Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program J Clin Oncol 21 4635 4641 14673053 10.1200/JCO.2003.04.070 1:CAS:528:DC%2BD2cXpsVWqurc%3D (Pubitemid 46594038)
35. JA Roscoe GR Morrow JT Hickok KM Mustian, et al. 2005 Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy Breast Cancer Res Treat 89 243 249 15754122 10.1007/s10549-004-2175-1 1:CAS:528:DC%2BD2MXitVKlsb0%3D (Pubitemid 43293071)
36. D Razavi JF Allilaire M Smith A Salimpour M Verra, et al. 1996 The effect of fluoxetine on anxiety and depression symptoms in cancer patients Acta Psychiatr Scand 94 205 210 8891089 10.1111/j.1600-0447.1996.tb09850.x 1:CAS:528:DyaK28Xmtlynuro%3D (Pubitemid 26313295)
37. K Van Heeringen M Zivkov 1996 Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin Br J Psychiatry 169 440 443 8894194 10.1192/bjp.169.4.440
38. G Pezzella R Moslinger-Gehmayr A Contu 2001 Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline Breast Cancer Res Treat 70 1 1 10 11766999 10.1023/A:1012518831494 1:CAS:528:DC%2BD38XmtVKmtA%3D%3D (Pubitemid 33105097)
39. MA Weitzner J Moncello PB Jacobsen SJ Minton 2002 A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer Pain Symptom Manage 23 4 337 345 10.1016/S0885-3924(02)00379- 2 1:CAS:528:DC%2BD38XosFSmur0%3D (Pubitemid 34462946)
40. P Chi-Un Y-J Kim W-Y Won H-J Kim, et al. 2004 Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study Hum Psychopharmacol Clin Exp 19-1 25 29 (Pubitemid 38159272)
41. JC Bloomer FR Woods RE Haddock MS Lennard T Tucker 1992 The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes Br J Clin Pharmacol 33 521 523 1388041 1:CAS:528:DyaK38Xktl2ktrg%3D
42. CM Kaye RE Haddock PF Langley, et al. 1989 A review of the metabolism and pharmacokinetics of paroxetine in man Acta Psychiatr Scand 80 350 60 75 10.1111/j.1600-0447.1989.tb07176.x (Pubitemid 19236643)
43. AJ Wagstaff SM Cheer AJ Matheson D Ormrod Kl Goa 2002 Paroxetine: an update of its use in psychiatric disorders in adults Drugs 62 655 703 11893234 10.2165/00003495-200262040-00010 1:CAS:528:DC%2BD38XjtVCgtLw%3D (Pubitemid 34264033)
44. DL Musselman WI Somerset Y Guo AK Manatunga, et al. 2006 A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression J Clin Psychiatry 67 2 288 296 16566626 10.4088/JCP.v67n0217 1:CAS:528: DC%2BD28XjsFOlsrs%3D (Pubitemid 43357477)